By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:







CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III


Please click here for clinical trial information.

Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
FDA Approves Genentech (RHHBY)'s RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology 6/23/2017 6:25:35 AM
New Data At EAN Show Genentech (RHHBY)’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis 6/23/2017 6:03:52 AM
Genentech (RHHBY) Wins No. 1 Top Spot as The Ideal Employer in Life Sciences 6/22/2017 11:27:43 AM
Vital Art And Science Announces License Agreement With Genentech (RHHBY) For Its mVT Service 6/19/2017 9:26:39 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
NewLink Genetics (NLNK) Stock Plunges After Genentech (RHHBY) Bails on $1 Billion+ IDO Deal 6/8/2017 5:47:08 AM
Genentech (RHHBY)’s Perjeta-Based Adjuvant Breast Cancer Care Shows Minor Improvement, Puma Biotech (PBYI) Shares Jump 6/6/2017 6:26:19 AM
Phase III Study Showed Genentech (RHHBY)’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer 6/5/2017 7:01:52 AM
Puma Biotech (PBYI) Gets A Leg Up As Genentech (RHHBY) Suffers Blow Over Breast Cancer Combo Therapy 6/5/2017 6:42:56 AM
APHINITY Study Shows Genentech (RHHBY)’s Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer 6/5/2017 6:35:11 AM